1. In acute pancreatitis resuscitation, lactated Ringer's is preferred over 0.9% normal saline. Which property of lactated Ringer's accounts for this preference?
A) Its higher chloride concentration, which accelerates renal excretion of inflammatory mediators
B) Its buffering capacity and lower chloride load, which avoid the hyperchloremic metabolic acidosis associated with large-volume saline
C) Its hypotonicity relative to plasma, which preferentially reduces pancreatic interstitial edema
D) Its dextrose content, which supplies the metabolic substrate depleted during pancreatic inflammation
E) Its higher osmolality, which draws third-space fluid back into the intravascular compartment
ANSWER: B
Rationale:
The property that distinguishes lactated Ringer's (LR) is its buffering capacity—lactate is metabolized to bicarbonate—combined with a lower chloride load than 0.9% saline. Large-volume saline produces a hyperchloremic metabolic acidosis associated with greater systemic inflammatory response activation, and avoiding that acidosis is the mechanistic basis for preferring LR.
Option A: Option A is incorrect: it is the high chloride load of saline, not LR, that contributes to acidosis; chloride does not accelerate mediator clearance.
Option C: Option C is incorrect: LR is approximately isotonic, not hypotonic, and reducing pancreatic edema is not its mechanism.
Option D: Option D is incorrect: standard LR does not contain dextrose, and substrate supply is not the rationale.
Option E: Option E is incorrect: LR is not hyperosmolar, and osmotic intravascular pull is not the basis for its preference.
2. Antibiotic therapy in acute pancreatitis is reserved for a narrow set of indications. Which of the following is a validated indication for antibiotics?
A) Sterile pancreatic necrosis involving more than 30% of the gland
B) Persistent systemic inflammatory response syndrome without a documented source of infection
C) A peak C-reactive protein value above 150 mg/L on day 3
D) Confirmed infected pancreatic necrosis
E) Predicted severe disease by a validated scoring system at admission
ANSWER: D
Rationale:
Confirmed infected pancreatic necrosis (positive fine-needle aspiration culture, or gas within a necrotic collection with clinical deterioration) is a validated indication for antibiotics, as is concurrent cholangitis.
Option A: Option A is incorrect: sterile necrosis—regardless of extent—does not warrant antibiotics, because prophylaxis in sterile necrosis provides no benefit.
Option B: Option B is incorrect: SIRS (a generalized inflammatory state) commonly occurs without infection and does not by itself justify antibiotics.
Option C: Option C is incorrect: C-reactive protein is a nonspecific marker and is not an antibiotic indication.
Option E: Option E is incorrect: predicted severity does not establish infection and is not an indication to treat.
3. In acute pancreatitis requiring nutritional support, which route is preferred when the gut is functional?
A) Enteral nutrition
B) Total parenteral nutrition through a central catheter
C) Peripheral parenteral nutrition
D) Prolonged nil-per-os management with intravenous fluids only
E) Alternating enteral and parenteral nutrition on a daily cycle
ANSWER: A
Rationale:
Enteral nutrition is the preferred route in acute pancreatitis when the gut is functional. It maintains mucosal integrity, limits bacterial translocation, and reduces infectious complications compared with parenteral nutrition.
Option B: Option B is incorrect: total parenteral nutrition is reserved for patients in whom enteral access cannot be established or is not tolerated.
Option C: Option C is incorrect: peripheral parenteral nutrition is likewise a parenteral fallback, not the preferred route.
Option D: Option D is incorrect: prolonged starvation is harmful and is not protective against pancreatic stimulation.
Option E: Option E is incorrect: cycling between routes is not a recognized strategy and offers no advantage over preferred enteral feeding.
4. Pancreatic enzyme replacement therapy preparations contain lipase, protease, and amylase. Which component is dosed as the critical therapeutic element, and dosing is expressed in its units?
A) Amylase
B) Protease
C) Colipase
D) Trypsinogen
E) Lipase
ANSWER: E
Rationale:
Lipase is the critical therapeutic component of pancreatic enzyme replacement therapy, and dosing is expressed in lipase units. Fat digestion is the most severely impaired process in exocrine pancreatic insufficiency, and fat malabsorption produces the greatest nutritional morbidity.
Option A: Option A is incorrect: amylase deficiency is comparatively well tolerated, and dosing is not based on it.
Option B: Option B is incorrect: protease is present but is not the dose-limiting or dose-defining component.
Option C: Option C is incorrect: colipase is a cofactor for lipase, not the separately dosed therapeutic element.
Option D: Option D is incorrect: trypsinogen is an inactive zymogen precursor, not a dosing reference for replacement therapy.
5. For pancreatic enzyme replacement therapy to be effective, when should the enzymes be taken relative to meals?
A) Thirty minutes before the meal, on an empty stomach
B) At least one hour after the meal is finished
C) During the meal, distributed across the meal for large meals
D) Only at bedtime, independent of meal timing
E) Dissolved in a hot beverage taken just before eating
ANSWER: C
Rationale:
Enzymes must be taken during the meal so the enteric-coated microspheres mix with the food bolus, empty from the stomach with the chyme, and release in synchrony with nutrient delivery to the duodenum; for large meals the dose is split across the meal to improve mixing.
Option A: Option A is incorrect: taking enzymes before the meal on an empty stomach desynchronizes release from nutrient delivery.
Option B: Option B is incorrect: dosing after the meal misses the bolus and gives poor mixing.
Option D: Option D is incorrect: bedtime-only dosing is unrelated to meals and would not aid digestion.
Option E: Option E is incorrect: hot liquids can disrupt the enteric coating and inactivate the enzymes prematurely.
6. When an adequately dosed and correctly timed enzyme regimen still gives a suboptimal response in exocrine pancreatic insufficiency, which drug class is added to raise duodenal pH and improve enteric-coating dissolution?
A) A proton pump inhibitor
B) A bile acid sequestrant
C) An anticholinergic agent
D) A prokinetic agent
E) A nonsteroidal anti-inflammatory drug
ANSWER: A
Rationale:
A proton pump inhibitor is added when an optimized enzyme regimen still underperforms. Pancreatic bicarbonate deficiency lowers duodenal pH; raising it above the dissolution threshold allows the enteric coating to dissolve and prevents acid inactivation of the released enzymes.
Option B: Option B is incorrect: a bile acid sequestrant binds bile acids and would worsen fat absorption.
Option C: Option C is incorrect: anticholinergics are not used to enhance enzyme therapy and carry their own adverse effects.
Option D: Option D is incorrect: a prokinetic that accelerates transit would reduce enzyme–nutrient contact, not improve absorption.
Option E: Option E is incorrect: an NSAID does not raise duodenal pH and has no role in improving enzyme dissolution.
7. Octreotide and lanreotide produce their secretory-inhibitory effects by acting as agonists at which receptors?
A) Serotonin 5-HT3 receptors
B) Cholecystokinin receptors
C) Beta-2 adrenergic receptors
D) Somatostatin receptors, predominantly the SSTR2 and SSTR5 subtypes
E) Histamine H2 receptors
ANSWER: D
Rationale:
Octreotide and lanreotide are somatostatin analogues that act as agonists at somatostatin receptors, a family of G-protein-coupled receptors; most functional neuroendocrine tumors express the SSTR2 and SSTR5 subtypes at high density, which underlies the secretory-inhibitory effect.
Option A: Option A is incorrect: they are not serotonin receptor agents, although they reduce serotonin-mediated symptoms in carcinoid syndrome by suppressing mediator secretion.
Option B: Option B is incorrect: cholecystokinin receptors are not their target.
Option C: Option C is incorrect: they have no beta-2 adrenergic agonist activity.
Option E: Option E is incorrect: H2 receptors mediate gastric acid secretion and are unrelated to the somatostatin analogue mechanism.
8. Diazoxide suppresses insulin secretion in insulinoma. What is its direct action on the pancreatic beta-cell membrane?
A) It blocks ATP-sensitive potassium channels, depolarizing the beta cell
B) It opens ATP-sensitive potassium channels, hyperpolarizing the beta cell
C) It blocks voltage-gated calcium channels directly, independent of membrane potential
D) It opens voltage-gated sodium channels, driving repetitive firing
E) It inhibits the sodium-potassium ATPase, collapsing the membrane gradient
ANSWER: B
Rationale:
Diazoxide opens (activates) ATP-sensitive potassium channels in the beta cell; the resulting potassium efflux hyperpolarizes the membrane, keeps voltage-gated calcium channels closed, and suppresses calcium-triggered insulin exocytosis.
Option A: Option A inverts the action: blocking these channels would depolarize the cell and promote insulin release.
Option C: Option C is incorrect: diazoxide does not directly block calcium channels; it prevents their opening indirectly via hyperpolarization.
Option D: Option D is incorrect: it does not open sodium channels or drive firing.
Option E: Option E is incorrect: it does not act on the sodium-potassium ATPase.
9. Which electrolyte abnormality is the hallmark of refeeding syndrome?
A) Hypernatremia
B) Hyperkalemia
C) Hypercalcemia
D) Hypermagnesemia
E) Hypophosphatemia
ANSWER: E
Rationale:
Hypophosphatemia is the hallmark of refeeding syndrome. Insulin-driven anabolism after carbohydrate reintroduction shifts phosphate into cells for ATP synthesis, depleting already-low serum levels; severe hypophosphatemia impairs ATP production and can cause rhabdomyolysis, respiratory failure, and arrhythmias.
Option A: Option A is incorrect: refeeding does not characteristically cause hypernatremia.
Option B: Option B inverts the direction: insulin shifts potassium into cells, producing hypokalemia, not hyperkalemia.
Option C: Option C is incorrect: hypercalcemia is not a defining feature.
Option D: Option D inverts the direction: refeeding produces hypomagnesemia from intracellular shift, not hypermagnesemia.
10. Which vitamin must be supplemented before or alongside refeeding in high-risk malnourished patients to prevent Wernicke encephalopathy?
A) Folate
B) Vitamin B12
C) Thiamine
D) Vitamin D
E) Vitamin K
ANSWER: C
Rationale:
Thiamine must be supplemented before or alongside refeeding because carbohydrate reintroduction sharply raises demand for thiamine as a cofactor in glucose metabolism; in a depleted patient this can precipitate Wernicke encephalopathy.
Option A: Option A is incorrect: folate deficiency causes megaloblastic anemia, not the refeeding-related neurological complication prevented here.
Option B: Option B is incorrect: B12 is not the vitamin given to prevent a refeeding neurological complication.
Option D: Option D is incorrect: vitamin D addresses calcium and bone metabolism, not Wernicke encephalopathy.
Option E: Option E is incorrect: vitamin K addresses coagulopathy, not this neurological risk.
11. Inadequately treated exocrine pancreatic insufficiency most characteristically causes deficiency of which group of vitamins?
A) The fat-soluble vitamins A, D, E, and K
B) The water-soluble B-complex vitamins
C) Vitamin C and the B vitamins together
D) Vitamin B12 in isolation
E) Folate and iron together
ANSWER: A
Rationale:
The fat-soluble vitamins A, D, E, and K are characteristically deficient in inadequately treated exocrine pancreatic insufficiency because their absorption depends on micelle formation, which fails when fat digestion is impaired.
Option B: Option B is incorrect: water-soluble B vitamins do not depend on fat digestion and are not the characteristic deficiency.
Option C: Option C is incorrect: vitamin C is water-soluble and is not specifically tied to fat malabsorption.
Option D: Option D is incorrect: B12 deficiency relates to intrinsic factor and the terminal ileum, not pancreatic fat maldigestion.
Option E: Option E is incorrect: folate and iron are absorbed in the proximal small intestine and are not the hallmark deficiency of fat malabsorption.
12. A VIPoma classically produces which triad of findings (the WDHA syndrome)?
A) Migratory necrolytic erythema, glossitis, and hyperglycemia
B) Flushing, diarrhea, and right-sided valvular heart disease
C) Recurrent peptic ulcers, diarrhea, and gastric acid hypersecretion
D) Watery diarrhea, hypokalemia, and achlorhydria
E) Fasting hypoglycemia, weight gain, and neuroglycopenic symptoms
ANSWER: D
Rationale:
A VIPoma produces the WDHA syndrome—watery diarrhea, hypokalemia, and achlorhydria—through vasoactive intestinal peptide-driven intestinal fluid and electrolyte hypersecretion.
Option A: Option A describes the glucagonoma syndrome (necrolytic migratory erythema, glossitis, hyperglycemia), not VIPoma.
Option B: Option B describes carcinoid syndrome (flushing, diarrhea, and tricuspid/pulmonary valve disease).
Option C: Option C describes Zollinger-Ellison syndrome from a gastrinoma (acid hypersecretion and ulcers).
Option E: Option E describes insulinoma (fasting hypoglycemia with neuroglycopenic symptoms), not the secretory diarrhea of VIPoma.
13. Among intravenous lipid emulsions used in parenteral nutrition, which feature is associated with a reduced incidence of PN-associated liver disease?
A) A pure soybean-oil base rich in n-6 polyunsaturated fatty acids
B) Inclusion of fish oil providing anti-inflammatory n-3 fatty acids
C) Maximizing total daily lipid calories to spare dextrose
D) Removing all lipid from the formulation permanently
E) Substituting all lipid calories with intravenous dextrose indefinitely
ANSWER: B
Rationale:
Fish-oil-containing mixed-oil emulsions supply anti-inflammatory n-3 fatty acids and are associated with a reduced incidence of PN-associated liver disease, and can reverse established cholestasis.
Option A: Option A is incorrect: pure soybean-oil emulsions are rich in pro-inflammatory n-6 fatty acids and are implicated in the disease, not protective.
Option C: Option C is incorrect: maximizing lipid calories does not reduce hepatic injury and may worsen it.
Option D: Option D is incorrect: permanently removing lipid risks essential fatty acid deficiency and is not the supported approach.
Option E: Option E is incorrect: indefinitely substituting dextrose for lipid causes its own metabolic and hepatic complications.
14. Enteral formulas are classified by degree of protein hydrolysis. Which category provides free amino acids and is reserved for severe malabsorption or short bowel syndrome?
A) Polymeric formula
B) Standard fiber-enriched formula
C) Blenderized whole-food formula
D) Semi-elemental formula
E) Elemental formula
ANSWER: E
Rationale:
Elemental formulas provide free amino acids with minimal fat (largely medium-chain triglycerides) and demand the least digestive and absorptive capacity, so they are reserved for severe malabsorption, short bowel syndrome, or minimal residual bowel.
Option A: Option A is incorrect: polymeric formulas contain intact protein and suit a functional gut.
Option B: Option B is incorrect: fiber-enriched standard formulas are intended for patients with adequate absorptive capacity.
Option C: Option C is incorrect: blenderized whole-food formulas require full digestive capacity.
Option D: Option D is incorrect: semi-elemental formulas contain partially hydrolyzed protein for moderate malabsorption, not the most severe cases.
15. Pregabalin is used as an opioid-sparing adjunct for chronic pancreatitis pain. What is its mechanism of action?
A) Agonism at mu-opioid receptors
B) Inhibition of cyclooxygenase-mediated prostaglandin synthesis
C) Binding to the alpha-2-delta subunit of voltage-gated calcium channels, reducing central pain sensitization
D) Blockade of N-methyl-D-aspartate glutamate receptors
E) Enhancement of descending serotonergic and noradrenergic inhibition through reuptake blockade
ANSWER: C
Rationale:
Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and central pain sensitization; this mechanism underlies its modest, opioid-sparing benefit in chronic pancreatitis pain.
Option A: Option A is incorrect: pregabalin has no opioid receptor agonism.
Option B: Option B is incorrect: cyclooxygenase inhibition is the mechanism of NSAIDs, not pregabalin.
Option D: Option D is incorrect: pregabalin does not act as an NMDA receptor antagonist.
Option E: Option E is incorrect: reuptake blockade of serotonin and norepinephrine describes serotonin-norepinephrine reuptake inhibitors, not pregabalin.
16. Which agent is given before and during a procedure to prevent carcinoid crisis in a patient with carcinoid syndrome?
A) Octreotide
B) Epinephrine
C) Hydrocortisone
D) Diphenhydramine
E) Metoprolol
ANSWER: A
Rationale:
High-dose octreotide given before induction and continued during the procedure is the standard prophylaxis against carcinoid crisis—a life-threatening surge of vasoactive mediators—and is also the treatment of choice for an established crisis.
Option B: Option B is incorrect: epinephrine can worsen mediator release and hemodynamic instability in carcinoid crisis and is not preventive.
Option C: Option C is incorrect: corticosteroids do not prevent the mediator surge that drives carcinoid crisis.
Option D: Option D is incorrect: an antihistamine does not block the broad range of vasoactive mediators involved.
Option E: Option E is incorrect: a beta-blocker does not prevent carcinoid crisis and may aggravate hypotension.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.